Numidargistat dihydrochloride
Based on 12 publication(s) in Google Scholar
Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
For research use only. We do not sell to patients.
- Purity: 98.50%
- Formula: C11H24BCl2N3O5
- Molecular Weight:360.04
-
Storage:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Covalent Screening Library
HY-L036
-
Orally Active Compound Library
HY-L061
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Boronic Acid Compound Library
HY-L167
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Amino Acid Metabolism Compound Library
HY-L189
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Numidargistat dihydrochloride
More- Cancer Cell. 2025 Feb 10;43(2):269-291.e19. [Abstract]
- Cell Death Dis. 2025 Dec 21. [Abstract]
- Cancer Lett. 2023 Jun 28:564:216208. [Abstract]
- Cell Commun Signal. 2023 Sep 18;21(1):236. [Abstract]
- Cancer Immunol Res. 2026 May 4;14(5):875-891. [Abstract]
- J Physiol. 2020 Nov;598(21):4907-4925. [Abstract]
- Res Sq. 2026 Feb 24.
- Patent. US20240307497A1.
- The University of Chicago. 2023 Dec.
- bioRxiv. 2024 Jul 31:2023.09.06.556606. [Abstract]
- Biomed Pharmacother. 2022 Sep:153:113321. [Abstract]
- Research Square Preprint. 2022 Mar.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Flow Cytometry
Biological Activity
IC50: 86 nM (Arginase 1), 296 nM (Arginase 2)[1]
Numidargistat dihydrochloride is a potent and orally-bioavailable inhibitor of arginase, with IC50s of 86 and 296 nM for recombinant human arginase 1 and 2, respectively. Numidargistat dihydrochloride inhibits native rginase 1 (Arg1) in human granulocyte, erythrocyte, and hepatocyte lysate with IC50s of 178 nM, 116 nM and 158 nM, respectively, and blocks Arg1 in cancer patient plasma (IC50, 122 nM). Numidargistat dihydrochloride also exhibits potent inhibitory activity against arginase in human HepG2, K562 cell lines and primary human hepatocytes with IC50s of 32, 139, 210 μM, respectively. Numidargistat dihydrochloride shows no effect on NOS. In addition, Numidargistat dihydrochloride is not directly cytotoxic to murine cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 360.04
-
Formula C11H24BCl2N3O5
-
Color White to yellow
-
SMILES
O=C([C@@H](N)C)N1C[C@H](CCCB(O)O)[C@](N)(C(O)=O)C1.Cl.Cl
-
Synonyms
CB-1158 dihydrochloride; INCB01158 dihydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. [Abstract]2025 Feb 10;43(2):269-291.e19. PMID: 39933899 -
Cell Death Dis
Tubule-derived CCN1 drives renal repair via αvβ5-STAT6-ARG1-dependent reprogramming of macrophages. [Abstract]2025 Dec 21. PMID: 41422302
Numidargistat dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Dec 21. [Abstract]
Numidargistat (50 μM; 48 h) significantly inhibited the upregulation of mRNA levels of growth factors including Igf1, Pdgfb, and Vegfa that were induced by CCN1 treatment in BMDMs.
Numidargistat dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Dec 21. [Abstract]
Numidargistat (50 μM; 48 h) suppressed the concentration of growth factors IGF-1 and PDGF-BB released from CCN1-treated BMDMs.
Numidargistat dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Dec 21. [Abstract]
Numidargistat (50 μM; 48 h) inhibited CCN1-induced increase in EdU+ proliferating cells in HK-2 cells co-cultured with BMDMs.
Numidargistat dihydrochloride purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Dec 21. [Abstract]
Numidargistat (50 μM; 48 h) significantly decreased the proportion of EdU+ HK-2 cells in BMDMs.
-
Cancer Lett
Myeloid-derived suppressor cells deficient in cholesterol biosynthesis promote tumor immune evasion. [Abstract]2023 Jun 28:564:216208. PMID: 37150500 -
Cell Commun Signal
Arginase-1 promotes lens epithelial-to-mesenchymal transition in different models of anterior subcapsular cataract. [Abstract]2023 Sep 18;21(1):236. PMID: 37723490 -
Cancer Immunol Res
CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer. [Abstract]2026 May 4;14(5):875-891. PMID: 41686262
Numidargistat dihydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Immunol Res. 2026 May 4;14(5):875-891. [Abstract]
Numidargistat (CB-1158) (10 µM; 48 h) significantly reversed the immunosuppressive effect on CD8+ T-cell proliferation.
-
J Physiol
Arginase 1 is involved in lacrimal hyposecretion in male NOD mice, a model of Sjögren's syndrome, regardless of dacryoadenitis status. [Abstract]2020 Nov;598(21):4907-4925. PMID: 32780506 -
-
-
-
bioRxiv
Myeloid-mesenchymal crosstalk drives Arg1-dependent profibrotic metabolism via ornithine in lung fibrosis. [Abstract]2024 Jul 31:2023.09.06.556606. PMID: 39211079 -
Biomed Pharmacother
Muscarinic acetylcholine receptors regulate inflammatory responses through arginases 1/2 in zebrafish. [Abstract]2022 Sep:153:113321. PMID: 35759868 -
Solvent & Solubility
DMSO : 55 mg/mL (152.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 37.78 mg/mL (104.93 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 3.25 mg/mL (9.03 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 3.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (277.75 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
Intracellular arginase activity is determined for the arginase-expressing HepG2 and K-562 cell lines as follows. HepG2 cells are seeded at 100,000 cells per well one day prior to treatment with CB-1158. K-562 cells are seeded at 200,000 cells per well on the day of CB-1158 treatment. Cells are treated with a dose-titration of CB-1158 in SILAC RPMI-1640 media containing 5% heat-inactivated and dialyzed FBS, antibiotics/anti-mycotic, 10 mM L-arginine, 0.27 mM L-lysine, and 2 mM L-glutamine. The medium is harvested after 24 h and urea generated is determined. Wells containing media without cells are used as background controls. For assessing the effect of CB-1158 on Arg1 in primary hepatocytes, frozen human hepatocytes are thawed, allowed to adhere onto collagen-coated wells for 4 h, and then incubated for 48 h in SILAC-RPMI containing 10 mM L-ornithine, no L-arginine, and a dose-titration of CB-1158, at which time the media are analyzed for urea[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[1]
For the 4T1 tumor model, 105 cells are injected orthotopically into the mammary fat pad; for all other tumor models, 106 cells are injected subcutaneously (s.c.) in the right flank. For all studies, CB-1158 is administered by oral gavage twice per day at 100 mg/kg starting on study day 1 (1 day after tumor implant). Control groups receive vehicle (water) twice daily by gavage. Tumor volume measured by digital caliper (length × width × width/2) and body weight are recorded three times per week. Mice are euthanized when tumors necrotize or volumes reach 2000 mm3. For the CT26 model, anti-PD-L1 antibody (5 mg/kg) is injected intraperitoneally (i.p.) on days 5, 7, 9, 11, 13, and 15. For the 4T1 model, anti-CTLA-4 antibody (5 mg/kg) is injected i.p. on days 2, 5, and 8; anti-PD-1 antibody (5 mg/kg) is injected i.p. on days 3, 6, and 9. 4T1 tumors are harvested on study day 25 into Fekete’s solution and tumor nodules are enumerated visually. LY 188011 is dosed 50 mg/kg i.p. on days 10 and 16 for the CT26 model, 60 mg/kg i.p. on days 6 and 10 for the LLC model, or 30 mg/kg i.p. on day 5 for the 4T1 model. With these regimens, LY 188011 modestly reduces tumor growth and spares most tumor-infiltrating immune cells, allowing for the evaluation of combination activity with CB-1158[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.7775 mL | 13.8873 mL | 27.7747 mL | 69.4367 mL |
| 5 mM | 0.5555 mL | 2.7775 mL | 5.5549 mL | 13.8873 mL | |
| 10 mM | 0.2777 mL | 1.3887 mL | 2.7775 mL | 6.9437 mL | |
| 15 mM | 0.1852 mL | 0.9258 mL | 1.8516 mL | 4.6291 mL | |
| 20 mM | 0.1389 mL | 0.6944 mL | 1.3887 mL | 3.4718 mL | |
| 25 mM | 0.1111 mL | 0.5555 mL | 1.1110 mL | 2.7775 mL | |
| 30 mM | 0.0926 mL | 0.4629 mL | 0.9258 mL | 2.3146 mL | |
| 40 mM | 0.0694 mL | 0.3472 mL | 0.6944 mL | 1.7359 mL | |
| 50 mM | 0.0555 mL | 0.2777 mL | 0.5555 mL | 1.3887 mL | |
| 60 mM | 0.0463 mL | 0.2315 mL | 0.4629 mL | 1.1573 mL | |
| 80 mM | 0.0347 mL | 0.1736 mL | 0.3472 mL | 0.8680 mL | |
| 100 mM | 0.0278 mL | 0.1389 mL | 0.2777 mL | 0.6944 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Numidargistat dihydrochloride Related Classifications
HY-101979A Related Classifications
Powered by Bioz